Well Referenced

Tag: Insulin Sensitivity

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

This 2022 mini-review discusses tirzepatide, a first-in-class dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, approved for type 2 diabetes and obesity management. Tirzepatide significantly reduces glycemic levels, improves insulin sensitivity, and promotes weight loss exceeding 20%, along with favorable effects on lipid metabolism. Its design

Read More »
June 26, 2025 No Comments

A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes

This 2013 review explores oxytocin (OXT) as a potential therapeutic agent for obesity and diabetes. Traditionally recognized for its role in reproduction, OXT has been found to influence metabolic regulation by acting on the hypothalamus to suppress appetite and increase energy expenditure. Animal studies demonstrate that OXT administration leads to

Read More »
June 26, 2025 No Comments

Phentermine/Topiramate Extended-Release Capsules (Qsymia) for Weight Loss

This 2013 review evaluates the efficacy and safety of phentermine/topiramate extended-release (PHEN/TPM ER) capsules, marketed as Qsymia, for obesity management. Clinical trials demonstrated significant weight loss ranging from 8.1% to 10.9% with mid to high doses, compared to 1.4% to 1.8% with placebo. PHEN/TPM ER also led to reductions in

Read More »
June 26, 2025 No Comments

MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism

This 2016 study introduces MOTS-c, a mitochondrial-derived peptide encoded within the 12S rRNA gene, highlighting its role in regulating metabolic homeostasis. MOTS-c enhances insulin sensitivity, promotes glucose utilization, and prevents high-fat diet-induced obesity and insulin resistance in mice. It primarily targets skeletal muscle but also influences adipose tissue, acting through

Read More »
June 26, 2025 No Comments

Supplementation with Akkermansia muciniphila in Overweight and Obese Human Volunteers: A Proof-of-Concept Exploratory Study

This 2019 randomized, double-blind, placebo-controlled pilot study evaluated the safety and metabolic effects of daily oral supplementation with 10¹⁰ CFU of either live or pasteurized Akkermansia muciniphila over three months in 32 overweight or obese insulin-resistant adults. Pasteurized A. muciniphila significantly improved insulin sensitivity (+28.6%, P=0.002), reduced fasting insulin levels

Read More »
June 26, 2025 No Comments

Effects of Exercise Amount and Intensity on Abdominal Obesity and Glucose Tolerance in Obese Adults: A Randomized Trial

This 2015 randomized controlled trial assessed the independent effects of exercise amount and intensity on abdominal obesity and glucose tolerance in 300 abdominally obese adults over 24 weeks. Participants were assigned to one of four groups: control (no exercise), low-amount low-intensity (LALI), high-amount low-intensity (HALI), or high-amount high-intensity (HAHI) exercise.

Read More »
June 26, 2025 No Comments

The Role of Resveratrol Administration in Human Obesity

This 2021 review article evaluates clinical studies on resveratrol supplementation in overweight and obese individuals. Resveratrol, a polyphenolic compound, exhibits antioxidant, anti-inflammatory, and metabolic regulatory properties. Clinical trials suggest that resveratrol may improve insulin sensitivity, reduce oxidative stress, and modulate adipogenesis through pathways involving SIRT1 activation and AMPK signaling. However,

Read More »
June 26, 2025 No Comments

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

This 2011 randomized, double-blind, placebo-controlled crossover study examined the effects of 150 mg/day resveratrol supplementation over 30 days in 11 healthy obese men. Resveratrol significantly reduced sleeping and resting metabolic rates. In skeletal muscle, it activated AMPK, increased SIRT1 and PGC-1α protein levels, and enhanced mitochondrial respiration on fatty acid-derived

Read More »
June 26, 2025 No Comments

A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder: results of the Binge Eating and Chromium (BEACh) study

This 6-month double-blind, randomized, placebo-controlled pilot trial assessed the effects of chromium picolinate supplementation on binge eating disorder (BED) in 24 overweight adults. Participants were randomized to receive either 1000 mcg/day (high dose), 600 mcg/day (moderate dose), or placebo. The moderate dose group exhibited significant reductions in fasting glucose levels

Read More »
June 26, 2025 No Comments

Chromium Effects on Glucose Tolerance and Insulin Sensitivity in Persons at Risk for Diabetes Mellitus

This 2011 randomized, double-blind, placebo-controlled trial evaluated the effects of daily chromium picolinate supplementation (500 μg or 1000 μg) over six months in 59 adults with impaired fasting glucose, impaired glucose tolerance, or metabolic syndrome. The study found no significant improvements in fasting plasma glucose, 2-hour plasma glucose, fasting or

Read More »
June 26, 2025 No Comments